Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07681271 Remibrutinib Rosacea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07681271 clinical trial report covering Remibrutinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07682454 Trinitrate Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07682454 clinical trial report covering Trinitrate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07681674 BT-7480 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07681674 clinical trial report covering BT-7480, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07682129 ENTR-601-45 Muscular Dystrophy, Duchenne Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07682129 clinical trial report covering ENTR-601-45, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07680764 Pumitamig metastatic non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07680764 clinical trial report covering Pumitamig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07681089 Foscenvivint Hemophilia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07681089 clinical trial report covering Foscenvivint, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07681869 Nimodipine Alcohol Use Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07681869 clinical trial report covering Nimodipine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07680322 AV-078 Epilepsy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07680322 clinical trial report covering AV-078, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07680790 Izalontamab Brengitecan EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07680790 clinical trial report covering Izalontamab Brengitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07680088 Pembrolizumab squamous cell carcinoma of the anus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07680088 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07681167 Faricimab Central Serous Chorioretinopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07681167 clinical trial report covering Faricimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262589 DR-10624 Hypertriglyceridemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262589 clinical trial report covering DR-10624, Phase 2, endpoints, sponsor, geography, readout timing and development white space.